Research background and project basis
Since the end of 2019, the coronavirus disease 2019 (COVID-19) has spread nationally and globally. COVID-19 is primarily caused by a β-coronavirus infection called SARS-CoV-2 and can affect systems throughout the body, but mostly the lungs. Patients with lung cancer experience more severe symptoms after infection with SARS-CoV-2, possibly because SARS-CoV-2 can reshape the lung cancer microenvironment and trigger a severe cytokine storm. Patients with lung cancer, especially those receiving anti-tumor therapy with chemoradiotherapy, are immunosuppressed and are more susceptible to SARS-CoV-2. With the release of China’s epidemic prevention policy and the evolution of SARS-CoV-2, it is more urgent to study the impact of COVID-19 on the immune system of lung cancer patients.
Research purpose
To explore the effects of novel coronavirus on the immune function and status of lung cancer patients, and to provide evidence-based evidence for immunotherapy and other anti-tumor therapy of lung cancer patients after recovery from novel coronavirus infection.